# A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer

> **NCT07736612** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang University** · enrollment: 80 (estimated)

## Conditions studied

- Pancreatic Cancer
- RAS Mutations or Amplifications

## Interventions

- **DRUG:** HRS-2329 Tablet
- **DRUG:** Nimotuzumab
- **DRUG:** HS-20093
- **DRUG:** Adebrelimab

## Key facts

- **NCT ID:** NCT07736612
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-15
- **Primary completion:** 2028-08-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07736612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07736612, "A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07736612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*